Recently, the DESTINY-Breast 04 trial has shown a significant clinical benefit of therapy with ADC trastuzumab deruxtecan (T-DXd) in patients with advanced breast cancer (aBC) with low HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.